论文部分内容阅读
目的分析伊曲康唑治疗恶性血液病患者侵袭性真菌感染(IFI)的疗效和安全性。方法选择四川省人民医院血液科2006-02/2009-06住院的72例恶性血液病并发IFI患者,其中,男46例、女26例,中位年龄42岁。确诊或拟诊真菌感染或经验性治疗者使用伊曲康唑,剂量为:每次200mg,静脉滴注,1次/12h;用2d后,每次200mg,1次/d,完成疗程7d以上评价疗效。完成者共53例,疗程为732d,中位数14d。结果 53例完成疗程患者中:痊愈15例,显效19例,进步5例,无效14例,有效率为64.15%(34/53);不良反应发生率19.44%(14/72),主要表现为心血管系统、消化系统、皮肤的症状,均为一过性。结论伊曲康唑治疗恶性血液病患者IFI具有广谱抗真菌功效,其引发的不良事件较少,安全性高。
Objective To analyze the efficacy and safety of itraconazole in the treatment of invasive fungal infection (IFI) in patients with hematologic malignancies. Methods 72 cases of hematologic malignancies complicated by IFI admitted to Department of Hematology, Sichuan Provincial People ’s Hospital from February 2006 to June 2009 were selected, 46 males and 26 females with a median age of 42 years. Diagnosed or suspected fungal infection or empirical treatment of itraconazole dose: each 200mg, intravenous infusion, 1 / 12h; with 2d, each 200mg, 1 / d, to complete the treatment of more than 7d Evaluation of efficacy. Completed a total of 53 cases, 732d course of treatment, the median 14d. Results Among the 53 patients who completed the treatment, 15 cases were cured, 19 cases were markedly improved, 5 cases were improved and 14 cases were ineffective. The effective rate was 64.15% (34/53). The incidence of adverse reactions was 19.44% (14/72) Cardiovascular system, digestive system, skin symptoms, are transient. Conclusion Itraconazole has a broad-spectrum antifungal efficacy against IFI in patients with hematologic malignancies, with fewer adverse events and high safety.